Addiction & Substance Use

Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.

Nearly half of US adults who drink and use cannabis combine them at once; cannabis use disorder drives the trend, signaling urgent screening needs.

FDA grants Breakthrough Device status to NET Recovery’s tACS wearable, aiming to curb cocaine and meth use and close a major treatment gap.

International Overdose Awareness Day marks 25 years, spotlighting fragile declines in deaths and urging naloxone access, harm reduction funding, and stigma-free care.

Axsome launches SUMMIT phase 3 testing AXS-05 to help adults quit smoking, comparing it with bupropion and placebo over 12 weeks.

Review news in psychiatry from the last week.

Clinicians weigh benzodiazepine benefits against dependence fears, with expert guidance on safe prescribing, withdrawal tapering, and long-term anxiety treatment choices.

See the latest in this psychiatric news roundup.

PleoPharma secures $6.5M NIDA grant to advance phase 3 PP-01 trial, aiming to ease cannabis withdrawal and address untreated cannabis use disorder.

Long-acting injectable buprenorphine cuts missed doses, boosts retention, and protects patients during high-risk transitions in the fentanyl era.

Urine drug screenings are often misordered and misread, risking stigma and harm; learn immunoassay limits, confirmatory testing basics, and when testing truly helps.

Learn why varenicline leads smoking cessation products in bipolar disorder, with reassuring safety data and practical strategies when quitting proves difficult.

Retrospective cohort study of 1305 adults finds specialized virtual behavioral health care produced clinically meaningful gambling symptom improvement within 14 days.

Share insights on substance use care—practice tips, research, and cases—for Psychiatric Times’ July 2026 series. Pitch your article today.